Review
References
|
Adams GP, Weiner LM (2005). Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23:1147-1157. |
|
|
Belardell F (1995). Role of interferons and other cytokines in the regulation of the immune response. APMIS, 103:161-79. |
|
|
Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002). Interferon-alpha in tumor immunity and immunotherapy. Cytokine and Growth Factor Rev. 13:119-134. |
|
|
Bisht M, Bist SS, Dhasmana DC (2010). Biological response modifiers: Current use and future prospects in cancer therapy. Indian J. Cancer, 47(4):443-451. |
|
|
Boon T, Coulie PG, Van-den Eynde BJ, van der Bruggen P (2006). Human T cell responses against melanoma. Annu. Rev. Immunol. 24:175-208. |
|
|
Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 101(19):1348-55. |
|
|
Clark JW, Smith JW, Steis RG (1990). Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 50:7343-7350. |
|
|
Dimberu PM, Leonhardt RM (2011). Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J. Biol. Med. 84:371-380. |
|
|
Drake CG (2009). Immunotherapy for prostate cancer. J. Clin. Onco. 27:4035-4037. |
|
|
Drake CG (2010). Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10:580-593. |
|
|
Dudley ME, Wunderlich JR, Yang JC (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357. |
|
|
Emeryville CA (2008). Proleukin. Bayer HealthCare Pharmaceuticals, Inc. |
|
|
Fang L, Lonsdorf AS, Hwang ST (2008). Immunotherapy for advanced melanoma. J. Invest. Dermatol. 128:2596-2605. |
|
|
Fishman M (2009). A changing world for DCVax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin. Biol. Ther. 9:1565-1575. |
|
|
Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004). Complement function in mAb-mediated cancer immunotherapy. Trends Immunol, 25:158-164. |
|
|
Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P (2011). Cancer Immunotherapy: Sipuleucel-T and Beyond. Pharmacotherapy 31(8):813-828. |
|
|
Hausen HZ (2009). Papillomaviruses in the causation of human cancers: A brief historical account. Virol. 384(2):260-265. |
|
|
Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ (2008). Phase 1or 2 dose escalation study of a GM-CSF secreting, allogeneic and cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975-984. |
|
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723. |
|
|
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28: 1099-10105. |
|
|
Kipp RT, McNeel DG (2007). Immunotherapy for prostate cancer: Recent progress in clinical trials. Clin. Adv. Hematol. Oncol. 5:465-479. |
|
|
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ (2008). Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26(20):3445-3455. |
|
|
Kreitman RJ, Pastan I (2011). Antibody-fusion proteins: Anti-CD22 recombinant immunotoxin: Moxetumomab pasudotox. Clin. Cancer Res. 17:6398-63405. |
|
|
Krieg AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760. |
|
|
Krieg AM (2006).Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5:471- 484. |
|
|
Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL, Prostvac VF (2009). A vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18:1001-1011. |
|
|
Marie LH, Haynes L, Parker C, Iversen P (2012). Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104:1-7. |
|
|
Marrari A, Iero M, Pilla L (2007). Vaccination therapy in prostate cancer. Cancer Immunol. Immunother. 56:429-445. |
|
|
McNeel DG (2007). Active specific immunotherapy in cancer: Cellular immunotherapies for prostate cancer. Biomed. Pharmacother. 61:315-322. |
|
|
Mellman I, Coukos G, Dranoff G (2011). Cancer immunotherapy comes of age. Nature 480(7378):480-489. |
|
|
Melton RG, Sherwood RF (1996). Antibody enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88(3-4):153-165. |
|
|
Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G (1999). Type-I IFN receptor: Structure, function and evolution of a family business. J. Interferon Cytokine Res. 19:1069-1098. |
|
|
Pardoll D, Drake C (2012). Immunotherapy earns its spot in the ranks of cancer therapy. J. Exper. Med. 209(2):201-209. |
|
|
Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN (2006). Phase II trial of a toll-like receptor 9-activating oligonucleotides in patients with metastatic melanoma. J. Clin. Oncol. 24(36):5716-5724. |
|
|
Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58:2489-2499. |
|
|
Reinis M (2008). Biovax ID, a personalized therapeutic vaccine against B-cell lymphomas. Curr. Opin. Mol. Ther. 10:526-534. |
|
|
Rescigno M, Avogadri F, Curigliano G (2007). Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta 1776:108-123. |
|
|
Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005). Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP. J. Clin. Onco. 23(35):8968-8977. |
|
|
Rosenberg SA, Dudley ME (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opinion Immunol. 21:233-240. |
|
|
Rosenberg, SA, Yang JC, Restifo NP (2004). Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10(9):909-915. |
|
|
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308. |
|
|
Sarid R, Gao SJ (2011). Viruses and human cancer: From detection to causality. Cancer Lett. 305(2):218-227. |
|
|
Schuster SJ, Neelapu SS, Guase BL, Muggia FM, Gockerman JP, Sotomayor EM, Winter JN, Flowers CR, Stergiou AM, Kwak LW (2009). Idiotype vaccine therapy (Biovax ID) in follicular lymphoma in first complete remission: phase III clinical trial results. J. Clin. Oncol. 27:18. |
|
|
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P (2011). gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 365(8):771. |
|
|
Sharma P, Wagner K, Wolchok JD, Allison JP (2011). Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nature reviews Cancer 24:(11):805-812. |
|
|
Teicher BA, Chari RVJ (2011). Antibody conjugate therapeutics: Challenges and Potential. Clin. Cancer Res. 17:6389-6397. |
|
|
Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK (2008). C-100-21 study group phase III comparison of vitespen: An autologous tumor derived heat shock protein gp96 peptide complex vaccine with physician's choice of treatment for stage IV melanoma. J. Clin. Oncol. 26(6):955-962. |
|
|
Todar K (2008). Immune defense against bacterial pathogens: Adaptive or acquired immunity. Todar's Online Textbook of Bacteriology. |
|
|
Van Meir EG, Hadjipanayis CG, Norden AD, Shu Hui-Kuo Wen PY, Olson JJ (2010). Exciting new advances in Neuro-oncology: The avenue to a cure for malignant glioma. CA. Cancer J. Clin. 60(3):166-193. |
|
|
Waldmann TA (2003). Immunotherapy: Past, present and future. Nat. Med. 9(3):269-277. |
|
|
Waller EK (2007). The Role of Sargramostim (rhGM-CSF) as Immunotherapy. The Oncologist 12(2):22-26. |
|
|
Weiner LM, Surana R, Wang S (2010). Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10:317-327. |
|
|
West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, Prescott AR, Watts C (2004). Enhanced dendritic cell antigen capture via toll-like receptor induced actin remodeling. Sci, 305 (5687):1153-1157. |
|
|
Wheeler CJ, Black KL (2009). DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin. Investig. Drugs 18(4):509-519. |
|
|
Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B (2008). C-100-12 RCC study group an adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open label, randomised phase III trial. Lancet 372:145-154. |
|
|
Wrzesinski C, Paulos CM, Gattinoni L (2007). Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. J. Clin. Invest. 117:492-501. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
